Shares of Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) fell 27.3% during trading on Friday . The stock traded as low as $4.95 and last traded at $8.00. 2,110 shares traded hands during mid-day trading, an increase of 238% from the average session volume of 625 shares. The stock had previously closed at $11.00.
Propanc Biopharma Trading Down 27.3 %
The business’s 50 day moving average price is $6.64 and its 200-day moving average price is $3.02.
Propanc Biopharma Company Profile
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
Featured Stories
- Five stocks we like better than Propanc Biopharma
- What is diluted earnings per share (Diluted EPS)?
- J.B. Hunt Transport Overcorrects Into a Buying Opportunity
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- AppLovin: Can Record Profits Overcome Market Skepticism?
- Stock Analyst Ratings and Canadian Analyst Ratings
- MarketBeat Week in Review – 04/14 – 04/18
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
